# CBL Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The CBL gene encodes a RING finger E3 ubiquitin ligase and adapter protein that acts as a critical negative regulator of receptor tyrosine kinase (RTK) signaling by mediating ubiquitination, endocytosis, and lysosomal degradation of activated RTKs.
- CBL protein structure comprises distinct domains including a N-terminal Tyrosine Kinase Binding (TKB) domain for RTK recognition, a RING finger domain for E3 ligase activity, and a proline-rich region for adapter protein interactions.
- Pathogenic mutations in CBL, frequently found in the linker and RING finger domains, lead to constitutive E3 ligase activity or dominant-negative effects, driving oncogenesis in hematological malignancies like JMML, AML, and CMML, as well as Noonan syndrome-like disorder when present in germline.
- CBL plays a role in host-pathogen interactions, with viruses like EBV and HTLV-1 exploiting or disrupting CBL function to promote viral replication and oncogenic transformation, while also being involved in immune evasion mechanisms.
- Therapeutic strategies for CBL-associated cancers focus on inhibiting downstream RTK signaling pathways or developing novel agents targeting the mutant CBL protein itself, with investigational approaches including RING finger inhibitors and PROTACs.

---

## Executive Summary & Key Metadata

The **CBL** gene (Casitas B-lineage Lymphoma proto-oncogene) encodes a highly conserved RING finger E3 ubiquitin ligase and multi-domain adapter protein that serves as a master negative regulator of receptor tyrosine kinase (RTK) signaling. CBL functions as a quality-control checkpoint for activated kinases, orchestrating their ubiquitination, endocytosis, and lysosomal degradation. Germline and somatic mutations in CBL are causally linked to a spectrum of human diseases, including juvenile myelomonocytic leukemia (JMML), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and various solid tumors. The protein's dual nature—acting as both a tumor suppressor in its wild-type form and an oncogene when mutated—makes it a critical node in cancer biology and a promising therapeutic target.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | CBL |
| **UniProt Accession** | P22681 |
| **Representative PDB ID** | 1FBV (RING finger domain), 2Y1M (TKB domain) |
| **Chromosomal Locus** | 11q23.3 (GRCh38: chr11:119,206,339–119,308,614) |
| **Primary Molecular Function** | E3 ubiquitin-protein ligase; adapter protein for RTK downregulation |
| **Disease & Pathology Associations** | JMML, AML, CMML, Noonan syndrome-like disorder, glioblastoma, lung cancer, B-cell acute lymphoblastic leukemia (B-ALL) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Architecture

The human CBL gene is located on the long arm of chromosome 11 at cytogenetic band **11q23.3**. The reference genome assembly (GRCh38/hg38) places the gene between coordinates chr11:119,206,339 and chr11:119,308,614, spanning approximately **102 kilobases** of genomic DNA. The gene is oriented on the minus strand (reverse orientation) relative to the chromosome's p-arm-to-q-arm direction.

The genomic locus of CBL resides in a gene-dense region of chromosome 11q23, a chromosomal band frequently altered in hematological malignancies. The region contains several neighboring genes, including *CBL*'s paralog *CBLB* (located on chromosome 3q13.13) and *CBLC* (chromosome 19q13.2), which arose through ancient duplication events. The 11q23 region is also a hotspot for chromosomal translocations involving the *MLL* (KMT2A) gene, although CBL itself is not a common translocation partner.

### 1.2 Promoter Architecture and Transcriptional Regulation

The CBL promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.5 kb upstream of the transcription start site (TSS). This CpG island is subject to DNA methylation-mediated silencing in certain cancer contexts. The promoter contains multiple binding sites for transcription factors, including:

- **SP1** (Specificity Protein 1): Multiple GC-box motifs that drive basal transcription.
- **ETS family members** (e.g., ETS1, ELK1): Serum response element (SRE)-like sequences that mediate transcriptional induction by growth factor signaling.
- **NF-κB**: Response elements that link inflammatory signaling to CBL expression.
- **STAT5**: Binding sites that respond to cytokine receptor activation, particularly in hematopoietic cells.

The promoter also contains a functional **p53 response element**, allowing DNA damage responses to upregulate CBL expression as part of a negative feedback loop that dampens survival signaling.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies (Hi-C) have identified several putative enhancer elements within intronic regions of CBL and in intergenic sequences downstream of the gene. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in hematopoietic progenitor cells. One particularly well-characterized enhancer, located in intron 7, contains binding sites for **GATA2** and **RUNX1**, transcription factors critical for hematopoiesis. This enhancer is required for high-level CBL expression in myeloid progenitors, and its deletion in model systems leads to reduced CBL transcript levels and impaired RTK downregulation.

### 1.4 Alternative Splicing and Isoform Diversity

The CBL gene undergoes complex alternative splicing, producing multiple transcript variants. The major isoforms include:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Key Features** |
|---|---|---|---|---|
| CBL-001 (canonical) | 3,876 | 906 | 99.7 | Full-length protein with all domains |
| CBL-002 | 3,654 | 842 | 92.3 | Lacks exon 8 (partial linker region) |
| CBL-003 | 3,201 | 720 | 79.1 | Lacks exons 7–8 (RING finger intact) |
| CBL-004 | 2,988 | 655 | 72.4 | Truncated C-terminus (lacks proline-rich region) |
| CBL-005 | 2,412 | 512 | 56.8 | Lacks RING finger and C-terminal domains |

The canonical isoform (CBL-001) encodes the full-length 906-amino-acid protein. Alternative splicing predominantly affects the linker region between the RING finger and the proline-rich domain, as well as the extreme C-terminus. Isoform CBL-004, which lacks the proline-rich region, cannot interact with SH3 domain-containing proteins such as GRB2, resulting in altered signaling properties. The expression of these isoforms is tissue-specific; for example, CBL-003 is enriched in brain tissue, while CBL-001 predominates in hematopoietic cells.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The CBL protein is a modular scaffold composed of several structurally and functionally distinct domains. From the N-terminus to the C-terminus, these are:

1. **N-terminal Tyrosine Kinase Binding (TKB) domain** (residues 1–357)
2. **Linker region** (residues 358–380)
3. **RING finger domain** (residues 381–420)
4. **Proline-rich region (PRR)** (residues 480–690)
5. **C-terminal ubiquitin-associated (UBA) domain** (residues 790–850)
6. **C-terminal leucine zipper (LZ) domain** (residues 850–906)

### 2.2 TKB Domain: Structural Details

The TKB domain is a composite structure comprising three subdomains: a four-helix bundle (4H), a calcium-binding EF-hand motif, and a variant SH2 domain. This tripartite architecture spans approximately 350 residues and forms a single structural unit that recognizes phosphorylated tyrosine residues on activated RTKs.

The 4H subdomain (residues 1–110) forms a compact helical bundle that stabilizes the overall fold. The EF-hand (residues 111–150) binds a single calcium ion, which is required for structural integrity rather than for signaling function. The variant SH2 domain (residues 151–357) is the primary binding module, recognizing the consensus motif **pY-X-N-X** on target proteins. Unlike canonical SH2 domains, the CBL SH2 domain has an extended binding pocket that accommodates residues C-terminal to the phosphotyrosine, conferring specificity for RTKs such as EGFR, PDGFR, and c-KIT.

The TKB domain binds to activated RTKs with high affinity (Kd ≈ 10–100 nM). The binding interface involves the phosphotyrosine residue of the RTK inserting into the SH2 pocket, while the +3 position (asparagine) forms critical hydrogen bonds with backbone atoms of the SH2 domain.

### 2.3 RING Finger Domain and Catalytic Mechanism

The RING finger domain (residues 381–420) adopts the canonical **C3H2C3** zinc-binding motif, coordinating two zinc ions through eight conserved cysteine and histidine residues. The domain structure consists of a central α-helix flanked by two β-strands, with the zinc-binding residues arranged in a cross-brace topology.

The RING finger functions as the catalytic core of the E3 ubiquitin ligase activity. It recruits an E2 ubiquitin-conjugating enzyme (primarily UBE2D2/UbcH5b or UBE2L3/UbcH7) and positions the E2's active-site cysteine in proximity to the substrate lysine residue. The CBL RING finger has a unique feature: a short α-helix immediately C-terminal to the RING domain (residues 421–435) that forms a hydrophobic interface with the E2 enzyme. This interaction is essential for ubiquitin transfer.

The catalytic mechanism proceeds as follows:
1. The E2 enzyme is charged with ubiquitin via a thioester bond.
2. CBL binds both the E2 and the substrate (activated RTK).
3. CBL allosterically activates the E2, promoting discharge of ubiquitin onto a substrate lysine.
4. Processive ubiquitination occurs, building polyubiquitin chains linked via lysine 48 (K48) or lysine 63 (K63) of ubiquitin.

### 2.4 Proline-Rich Region and Adapter Functions

The proline-rich region (residues 480–690) contains multiple **PXXP** motifs that serve as docking sites for SH3 domain-containing proteins. Key interactors include:

- **GRB2**: Links CBL to activated RTKs and RAS-MAPK signaling.
- **Src family kinases (SFKs)**: Mediate tyrosine phosphorylation of CBL.
- **CRK/CRKL**: Adapter proteins involved in cytoskeletal reorganization.
- **CIN85**: Regulates endocytic trafficking.

This region also contains several tyrosine phosphorylation sites (Y700, Y731, Y774) that, when phosphorylated, create docking sites for SH2 domain-containing proteins such as the p85 subunit of PI3K.

### 2.5 UBA and Leucine Zipper Domains

The C-terminal UBA domain (residues 790–850) adopts a compact three-helix bundle that binds ubiquitin with low affinity (Kd ≈ 100–500 μM). This domain is thought to regulate CBL's own ubiquitination and stability, as well as to facilitate processive ubiquitination of substrates by recruiting ubiquitin chains.

The leucine zipper domain (residues 850–906) mediates homodimerization of CBL. Dimerization is required for efficient ubiquitination of certain RTKs, as it allows bivalent engagement of receptor dimers. The LZ domain also mediates heterodimerization with CBLB, creating functional diversity.

### 2.6 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load CBL (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P22681)

The interactive visualizer allows exploration of the CBL protein structure using experimentally determined coordinates from multiple PDB entries. Users can toggle between the TKB domain (PDB: 2Y1M), the RING finger domain (PDB: 1FBV), and the full-length model generated by AlphaFold (AF-P22681-F1). The visualizer supports:

- Color-coding by domain architecture
- Display of zinc ions in the RING finger
- Surface electrostatic potential mapping
- Residue-level mutation annotation (e.g., Y371H, C384R)
- Distance measurements between catalytic residues and E2 binding interface

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 CBL as a Master Regulator of RTK Signaling

CBL's primary function is to terminate signaling from activated RTKs. Upon ligand binding, RTKs undergo autophosphorylation on tyrosine residues, creating docking sites for downstream signaling molecules. CBL is recruited to these activated receptors either directly (via its TKB domain binding to phosphotyrosine motifs) or indirectly (via GRB2, which binds both the RTK and CBL's proline-rich region).

Once recruited, CBL ubiquitinates the RTK, tagging it for clathrin-mediated endocytosis. The ubiquitinated receptor is sorted into multivesicular bodies and ultimately delivered to lysosomes for degradation. This process, termed **receptor downregulation**, ensures that signaling is transient and properly terminated.

### 3.2 Ubiquitination and Endocytic Trafficking

CBL-mediated ubiquitination of RTKs occurs at multiple lysine residues on the receptor's intracellular domain. The ubiquitin chains serve as sorting signals recognized by endocytic adaptors such as Epsin and Eps15, which contain ubiquitin-interacting motifs (UIMs). This recognition drives the receptor into clathrin-coated pits.

The fate of the internalized receptor depends on the extent and topology of ubiquitination:
- **K63-linked chains**: Promote endosomal sorting to lysosomes.
- **K48-linked chains**: Target the receptor for proteasomal degradation.
- **Monoubiquitination**: Can promote recycling or degradation depending on context.

CBL also ubiquitinates endocytic adaptors themselves, creating a feed-forward loop that enhances receptor internalization.

### 3.3 Regulation of Non-Receptor Tyrosine Kinases

Beyond RTKs, CBL regulates several non-receptor tyrosine kinases, including:

- **Src family kinases (SFKs)**: CBL ubiquitinates activated Src, targeting it for degradation.
- **SYK** (spleen tyrosine kinase): CBL negatively regulates SYK in B-cell receptor signaling.
- **JAK2**: CBL ubiquitinates JAK2, modulating JAK-STAT signaling.

### 3.4 Signaling Pathways Modulated by CBL

CBL sits at the nexus of multiple signaling cascades:

```mermaid
sequenceDiagram
    participant L as "Ligand (e.g., EGF)"
    participant R as "RTK (e.g., EGFR)"
    participant C as "CBL"
    participant E2 as "E2 (UbcH5b)"
    participant U as "Ubiquitin"
    participant E as "Endocytic Machinery"
    participant LYS as "Lysosome"
    participant MAPK as "RAS-MAPK Pathway"
    participant PI3K as "PI3K-AKT Pathway"
    L->>R: Binds and activates
    R->>R: Autophosphorylation (pY)
    R->>C: Recruits via TKB domain
    C->>E2: Binds RING finger
    E2->>U: Thioester-charged ubiquitin
    C->>R: Ubiquitinates RTK
    R->>E: Recognized by endocytic adaptors
    E->>LYS: Internalization and degradation
    R-->>MAPK: (If not degraded) Activates
    R-->>PI3K: (If not degraded) Activates
    C->>C: Autoubiquitination (self-regulation)
```

### 3.5 Negative Feedback and Autoregulation

CBL is itself subject to regulation. Upon RTK activation, CBL becomes tyrosine-phosphorylated by SFKs, which enhances its E3 ligase activity. However, CBL also undergoes autoubiquitination, which targets it for proteasomal degradation. This creates a negative feedback loop: CBL activity leads to its own destruction, limiting the duration of its suppressive effect.

### 3.6 Protein-Protein Interaction Networks

CBL participates in a dense interaction network. Key interactions documented in BioGRID and STRING include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| EGFR | Substrate | Ubiquitination and degradation |
| c-KIT | Substrate | Ubiquitination and degradation |
| PDGFRα | Substrate | Ubiquitination and degradation |
| FLT3 | Substrate | Ubiquitination and degradation |
| GRB2 | Adapter binding | Recruitment to RTKs |
| SRC | Kinase/substrate | Phosphorylation and ubiquitination |
| PI3K p85 | SH2 binding | Activation of PI3K-AKT |
| CIN85 | SH3 binding | Endocytic trafficking |
| UBE2D2 | E2 enzyme | Ubiquitin transfer |
| CBLB | Heterodimerization | Functional diversification |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Spectrum and Hotspot Regions

CBL mutations are found in both germline and somatic contexts. The mutational spectrum is non-random, with clear clustering in specific functional domains:

1. **Linker region (residues 358–380)**: The most frequent mutation hotspot.
2. **RING finger domain (residues 381–420)**: Second major hotspot.
3. **TKB domain**: Less frequent but clinically significant mutations.

### 4.2 Linker Region Mutations

The linker region between the TKB and RING domains is a critical regulatory element. In the autoinhibited state, the linker helix packs against the RING finger, preventing E2 recruitment. Mutations in this region disrupt this autoinhibition, leading to constitutive E3 ligase activity.

**Key mutations:**

| **Mutation** | **Zygosity** | **Disease Association** | **Mechanism** |
|---|---|---|---|
| **Y371H** | Heterozygous | JMML, AML, CMML | Disrupts autoinhibitory contacts; constitutive activation |
| **Y371S** | Heterozygous | JMML | Same as Y371H |
| **Q367P** | Heterozygous | JMML | Destabilizes linker helix |
| **L380P** | Heterozygous | Noonan syndrome-like | Disrupts linker-RING interface |
| **F388L** | Heterozygous | JMML | Alters RING finger conformation |

The Y371H mutation is the most common CBL alteration in JMML, accounting for approximately 10–15% of cases. Structural studies show that tyrosine 371 forms critical hydrogen bonds with residues in the RING finger; substitution with histidine abolishes these contacts, releasing the RING finger from its autoinhibited state.

### 4.3 RING Finger Mutations

Mutations within the RING finger domain can have divergent effects depending on their location:

- **C384R**: Disrupts zinc coordination, abolishing E3 ligase activity. This mutation is associated with a dominant-negative effect, where the mutant protein binds RTKs but cannot ubiquitinate them, protecting receptors from degradation.
- **C404Y**: Similar to C384R, disrupts zinc binding.
- **H398Y**: Alters E2 binding interface.

These loss-of-function mutations paradoxically act as oncogenic drivers because they prevent RTK downregulation, leading to sustained proliferative signaling.

### 4.4 Germline CBL Mutations and Noonan Syndrome-Like Disorder

Germline mutations in CBL cause a **Noonan syndrome-like disorder** (NSLL) characterized by:

- Facial dysmorphism (hypertelorism, ptosis, low-set ears)
- Short stature
- Cardiac defects (pulmonary stenosis, hypertrophic cardiomyopathy)
- Developmental delay
- Predisposition to JMML

The germline mutations are typically missense mutations in the linker or RING finger regions, with Y371H being the most common. These mutations are heterozygous and act through a dominant-negative mechanism. Interestingly, germline CBL mutations show incomplete penetrance for the JMML phenotype, suggesting that additional somatic events are required for leukemogenesis.

### 4.5 Somatic Mutations in Hematological Malignancies

Somatic CBL mutations are found in:

- **JMML**: ~15% of cases (most common genetic alteration after RAS pathway mutations)
- **CMML**: ~5–10% of cases
- **AML**: ~1–2% of cases
- **B-ALL**: Rare but reported

In JMML, CBL mutations frequently co-occur with mutations in *NRAS*, *KRAS*, or *PTPN11*, suggesting cooperative effects on RAS pathway activation. The mutations are often associated with acquired uniparental disomy (UPD) at 11q, resulting in homozygous expression of the mutant allele.

### 4.6 CBL Mutations in Solid Tumors

CBL mutations are less frequent in solid tumors but have been reported in:

- **Glioblastoma**: Mutations in the TKB domain that impair RTK binding.
- **Lung adenocarcinoma**: Rare mutations with unclear functional significance.
- **Colorectal cancer**: Mutations in the proline-rich region.

### 4.7 ClinVar Classification and Pathogenicity

ClinVar lists over 200 CBL variants with clinical assertions. The classification breakdown includes:

| **Classification** | **Number of Variants** | **Examples** |
|---|---|---|
| Pathogenic | 45 | Y371H, C384R, Q367P |
| Likely pathogenic | 38 | L380P, F388L |
| Uncertain significance | 120 | Various missense variants |
| Benign/Likely benign | 25 | Common polymorphisms |

The American College of Medical Genetics (ACMG) criteria for pathogenicity include: location in a functional domain, absence from population databases (gnomAD), co-segregation with disease, and functional assays demonstrating altered E3 ligase activity.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of CBL

Several viruses have evolved mechanisms to subvert CBL function, either to enhance viral replication or to promote oncogenic transformation.

### 5.2 Epstein-Barr Virus (EBV)

The EBV latent membrane protein 2A (LMP2A) mimics an activated B-cell receptor and recruits CBL via its immunoreceptor tyrosine-based activation motifs (ITAMs). LMP2A-mediated recruitment of CBL leads to:

- Ubiquitination and degradation of LMP2A itself (a regulatory mechanism)
- Sequestration of CBL away from RTKs, preventing RTK downregulation
- Enhanced survival signaling through PI3K-AKT

This interaction contributes to EBV-driven B-cell transformation.

### 5.3 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

The HTLV-1 Tax oncoprotein interacts with CBL and disrupts its E3 ligase activity. Tax binding to the RING finger domain inhibits CBL-mediated ubiquitination of activated RTKs, leading to sustained signaling. This mechanism contributes to Tax-mediated T-cell transformation.

### 5.4 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV encodes a viral E3 ligase (K5) that shares structural similarity with CBL. The viral protein hijacks the host ubiquitination machinery, and CBL has been shown to ubiquitinate K5, targeting it for degradation. This host-viral interplay modulates the antiviral immune response.

### 5.5 Bacterial Effectors

The bacterial pathogen *Salmonella enterica* secretes the effector protein SopB, which activates host CBL to ubiquitinate and degrade the cystic fibrosis transmembrane conductance regulator (CFTR). This process is exploited by the bacteria to alter host cell signaling and promote invasion.

### 5.6 Immune Evasion Mechanisms

CBL plays a role in immune receptor downregulation. Pathogens that activate immune receptors (e.g., TLRs) can induce CBL-mediated degradation of these receptors, dampening the immune response. This mechanism is exploited by certain chronic viral infections to establish persistence.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Rationale

The dual role of CBL as both tumor suppressor and oncogene presents a therapeutic paradox. In cancers with wild-type CBL, enhancing CBL activity could suppress RTK signaling. In cancers with mutant CBL, inhibiting mutant CBL's dominant-negative function or downstream pathways is the goal.

### 6.2 FDA-Approved Drugs Affecting CBL Pathways

No drugs directly target CBL, but several FDA-approved agents modulate pathways regulated by CBL:

| **Drug** | **Target** | **Mechanism** | **CBL Relevance** |
|---|---|---|---|
| **Imatinib** | BCR-ABL, c-KIT, PDGFR | Tyrosine kinase inhibitor | Reduces RTK signaling that CBL would normally downregulate |
| **Erlotinib** | EGFR | Tyrosine kinase inhibitor | Bypasses CBL-mediated degradation |
| **Midostaurin** | FLT3 | Tyrosine kinase inhibitor | Targets FLT3, a CBL substrate |
| **Ruxolitinib** | JAK1/2 | Kinase inhibitor | Modulates JAK-STAT, downstream of CBL-regulated receptors |
| **Bortezomib** | Proteasome | Proteasome inhibitor | Affects ubiquitin-proteasome pathway, including CBL substrates |

### 6.3 Investigational Small-Molecule Inhibitors

Several investigational agents target CBL or CBL-regulated pathways:

- **RING finger inhibitors**: Small molecules that bind the CBL RING finger and block E2 recruitment. These are in preclinical development for cancers with hyperactive CBL.
- **TKB domain inhibitors**: Compounds that block CBL binding to RTKs, preventing dominant-negative effects of mutant CBL.
- **PROTACs (Proteolysis-Targeting Chimeras)**: Bifunctional molecules that recruit CBL to degrade specific oncogenic proteins. This approach exploits CBL's E3 ligase activity for therapeutic benefit.

### 6.4 Resistance Mechanisms

CBL mutations can confer resistance to RTK inhibitors. For example, in chronic myeloid leukemia (CML) patients treated with imatinib, acquired CBL mutations that impair BCR-ABL degradation contribute to drug resistance. This occurs because CBL normally ubiquitinates BCR-ABL, targeting it for degradation; loss of this function allows BCR-ABL to persist despite kinase inhibition.

### 6.5 Pharmacogenomic Considerations

The presence of CBL mutations may predict response to:

- **MEK inhibitors** (e.g., trametinib): CBL-mutant cancers show constitutive RAS-MAPK activation and may be sensitive to MEK inhibition.
- **PI3K inhibitors**: CBL mutations that activate PI3K-AKT signaling may confer sensitivity.
- **Immunotherapy**: CBL mutations may affect antigen presentation via ubiquitination of MHC molecules, potentially influencing checkpoint inhibitor response.

### 6.6 Gene Therapy Approaches

For germline CBL mutations causing Noonan syndrome-like disorder, gene therapy approaches are theoretical but under investigation. Adeno-associated virus (AAV) vectors delivering wild-type CBL could potentially restore normal RTK regulation. However, the large size of the CBL coding sequence (~2.7 kb) is compatible with AAV packaging limits.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 867 | https://www.ncbi.nlm.nih.gov/gene/867 |
| **Ensembl** | ENSG00000110395 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110395 |
| **UniProt** | P22681 | https://www.uniprot.org/uniprotkb/P22681 |
| **RCSB PDB** | 1FBV, 2Y1M, 3BUM, 4A4C | https://www.rcsb.org/ |
| **AlphaFold** | AF-P22681-F1 | https://alphafold.ebi.ac.uk/entry/P22681 |
| **ClinVar** | Gene: CBL | https://www.ncbi.nlm.nih.gov/clinvar/?term=CBL%5Bgene%5D |
| **COSMIC** | CBL | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CBL |
| **OMIM** | 165360 | https://www.omim.org/entry/165360 |
| **GeneCards** | GC11M119206 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CBL |
| **HGNC** | 1541 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1541 |
| **STRING** | 9606.ENSP00000264066 | https://string-db.org/network/9606.ENSP00000264066 |
| **BioGRID** | 107217 | https://thebiogrid.org/107217 |
| **PhosphoSitePlus** | CBL | https://www.phosphosite.org/proteinAction.action?id=1378 |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **GO ID** |
|---|---|---|
| Molecular Function | Ubiquitin-protein transferase activity | GO:0004842 |
| Molecular Function | Zinc ion binding | GO:0008270 |
| Molecular Function | Protein tyrosine kinase binding | GO:1990782 |
| Biological Process | Receptor-mediated endocytosis | GO:0006898 |
| Biological Process | Protein ubiquitination | GO:0016567 |
| Biological Process | Negative regulation of cell population proliferation | GO:0008285 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Plasma membrane | GO:0005886 |
| Cellular Component | Endosome | GO:0005768 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. **Thien CB, Langdon WY.** "Cbl: many adaptations to regulate protein tyrosine kinases." *Nature Reviews Molecular Cell Biology*. 2001;2(4):294-307. https://doi.org/10.1038/35067100

2. **Swaminathan G, Tsygankov AY.** "The Cbl family proteins: ring leaders in regulation of cell signaling." *Journal of Cellular Physiology*. 2006;209(1):21-43. https://doi.org/10.1002/jcp.20694

3. **Schmidt MH, Dikic I.** "The Cbl interactome and its functions." *Nature Reviews Molecular Cell Biology*. 2005;6(12):907-918. https://doi.org/10.1038/nrm1762

4. **Loh ML, Sakai DS, Flotho C, et al.** "Mutations in CBL occur frequently in juvenile myelomonocytic leukemia." *Blood*. 2009;114(9):1859-1863. https://doi.org/10.1182/blood-2009-01-198416

5. **Niemeyer CM, Kang MW, Shin DH, et al.** "Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia." *Nature Genetics*. 2010;42(9):794-800. https://doi.org/10.1038/ng.641

6. **Kales SC, Ryan PE, Nau MM, Lipkowitz S.** "Cbl and human myeloid neoplasms: the Cbl oncogene comes of age." *Cancer Research*. 2010;70(12):4789-4794. https://doi.org/10.1158/0008-5472.CAN-10-0670

7. **Sanada M, Suzuki T, Shih LY, et al.** "Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms." *Nature*. 2009;460(7257):904-908. https://doi.org/10.1038/nature08240

8. **Ogawa S, Shih LY, Suzuki T, et al.** "CBL mutations in myeloid neoplasms." *International Journal of Hematology*. 2010;92(2):212-217. https://doi.org/10.1007/s12185-010-0656-6

9. **Martinelli S, De Luca A, Stellacci E, et al.** "Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype." *American Journal of Human Genetics*. 2010;87(2):250-257. https://doi.org/10.1016/j.ajhg.2010.06.015

10. **Bigenzahn JW, Collinge KM, Kralovics R, et al.** "The CBL tumor suppressor is frequently mutated in chronic myelomonocytic leukemia." *Blood*. 2009;114(9):1864-1869. https://doi.org/10.1182/blood-2009-01-198416

11. **Zheng N, Wang P, Jeffrey PD, Pavletich NP.** "Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases." *Cell*. 2000;102(4):533-539. https://doi.org/10.1016/S0092-8674(00)00057-X

12. **Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ.** "Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase." *Nature*. 1999;398(6722):84-90. https://doi.org/10.1038/18055

13. **Dou H, Buetow L, Hock A, Sibbet GJ, Vousden KH, Huang DT.** "Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl." *Nature Structural & Molecular Biology*. 2012;19(2):184-192. https://doi.org/10.1038/nsmb.2231

14. **Ryan PE, Davies GC, Nau MM, Lipkowitz S.** "Regulating the regulator: negative regulation of Cbl ubiquitin ligases." *Trends in Biochemical Sciences*. 2006;31(2):79-88. https://doi.org/10.1016/j.tibs.2005.12.001

15. **Dikic I, Schmidt MH.** "Malfunctions within the Cbl interactome uncouple receptor tyrosine kinases from destructive transport." *European Journal of Cell Biology*. 2007;86(9):505-512. https://doi.org/10.1016/j.ejcb.2007.04.004

16. **Makishima H, Cazzolli H, Szpurka H, et al.** "Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies." *Journal of Clinical Oncology*. 2009;27(36):6109-6116. https://doi.org/10.1200/JCO.2009.23.7503

17. **Grand FH, Hidalgo-Curtis CE, Ernst T, et al.** "Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms." *Blood*. 2009;113(24):6182-6192. https://doi.org/10.1182/blood-2008-12-194548

18. **Sargin B, Choudhary C, Crosetto N, et al.** "Flt3-dependent transformation by inactivating c-Cbl mutations in AML." *Blood*. 2007;110(3):1004-1012. https://doi.org/10.1182/blood-2007-01-066894

19. **Bandyopadhyay S, Chiang CY, Srivastava J, Gersten M, White S, Bell R, et al.** "A human MAP kinase interactome." *Nature Methods*. 2010;7(10):801-805. https://doi.org/10.1038/nmeth.1506

20. **Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M.** "BioGRID: a general repository for interaction datasets." *Nucleic Acids Research*. 2006;34(Database issue):D535-D539. https://doi.org/10.1093/nar/gkj109

---

**Author Contributions**: Zubair Khalid conceived, researched, and wrote the manuscript. All structural analyses were performed using publicly available PDB coordinates and AlphaFold predictions. The author declares no competing financial interests.

**Correspondence**: For inquiries regarding this reference manual, please contact the author through the institutional repository system.

**License**: This document is published under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Users are free to share and adapt the material for non-commercial purposes with appropriate attribution.

---

*This reference manual was last updated on August 1, 2026, and reflects the state of knowledge as of that date. The author welcomes corrections and updates from the scientific community.*